MedTrace Logo

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

NCT01564862 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 602

Last updated 2015-02-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

vortioxetine (Lu AA21004)

Lu AA21004 capsules

DRUG

Duloxetine

Duloxetine capsules

DRUG

Placebo

Placebo matching capsules

Sponsors & Collaborators

Principal Investigators

  • Senior Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States
  • Bulgaria
  • Finland
  • Germany
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01564862 on ClinicalTrials.gov